Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Retained Earnings (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Retained Earnings for 2 consecutive years, with -$11.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Retained Earnings changed N/A year-over-year to -$11.5 million, compared with a TTM value of -$11.5 million through Jun 2025, changed N/A, and an annual FY2024 reading of -$8.8 million, changed N/A over the prior year.
  • Retained Earnings was -$11.5 million for Q2 2025 at Kairos Pharma, down from -$10.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$7.8 million in Q3 2024 and bottomed at -$11.5 million in Q2 2025.